The Oxford University and AstraZeneca COVID-19 vaccine has been found to be 79% effective in a large US trial for preventing symptomatic illness, and 100% effective against severe or critical disease and hospitalization.

An independent safety committee carried out a review of the blood clots in the US trial, and cerebral venous sinus thrombosis (CVST), with the help of an independent neurologist, reported the company. Among over 21,000 individuals who were administered at least one dose of the vaccine, there was no increased risk of thrombosis or events characterized by thrombosis. The specific search for CVST could identify no events in the trial, stated the firm… (Mint, March 22, 2021)